Scientific Advisory Board

Our experienced Scientific Advisory Board team has extensive experience in a variety of areas, including scientific discoveries, therapeutic product developments, and biotechnology innovations.

• Edward P. Amento, M.D., Director, Molecular Medicine Research Institute (MMRI); Clinical Professor of Medicine (Immunology/Rheumatology) and Dermatology, Stanford School of Medicine. Formerly founder and President of Connetics Corporation [Nasdaq: CNCT]; Program Head, Genentech; Assistant Professor of Medicine, Harvard Medical School.
  
  
• Barry M. Sherman, M.D., former Director, Clinical Research, Vice President, Medical Affairs, and Chief Medical Officer of Genentech. Former Professor of Medicine and Endocrinology at the University of Iowa College of Medicine where he served as Associate Chairman of the Department of Internal Medicine and Director of the NIH sponsored Clinical Research Center. More than 30 years experience in academic and pharmaceutical biomedical research.
  
  
• Dan Shochat, Ph.D. led the development of Bexxar®, a radioiodinated antibody for the treatment of Non-Hodgkin's Lymphoma, which was approved by the FDA in June 2003. At American Cyanamide Co., Dr. Shochat led the development, in collaboration with Celltech, of the first approved antibody-drug conjugate, Mylotarg®; Invented the technology and single-vial formulation, and then developed the FDA-approved in vivo tumor-imaging reagent CEA-Scan®. Dr. Shochat is currently Executive Vice President of Development of KaloBios, Inc. Formerly, Dr. Shochat was Director, Product R&D, Immunomedics; Director of Biotechnology Development at American Cyanamid Co.; Senior Vice President and Chief Scientific Officer Coulter Pharmaceutical, Inc.; Ph.D. in Biochemistry from L.S.U. Medical School in New Orleans, LA.
  
  
• Dr. Judith L. Swain is currently Dean for Translational Medicine and the Founding Director of the College of Integrated Life Sciences (COILS) at the University of California, San Diego. In September, 2006 she will become the Executive Director of the Singapore Institute for Clinical Sciences within A*STAR. Prior to UCSD, Dr. Swain served as Chair of the Department of Medicine at Stanford University. She is widely known in the field of molecular cardiology, and pioneered the use of transgenic animals to understand the genetic basis of cardiovascular development and disease. She serves as a director or member of the scientific advisory boards for a number of biomedical technology companies, and is co-founder of Synecor, LLC a medical device incubator company. Dr. Swain has been elected to a number of honorary societies including the Institute of Medicine.